Stock Analiz

IRulya Therapeutics Inc. IRLA

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026

$39.80Market cap $431M
Open the interactive analysis →

IRulya Therapeutics Inc. (IRLA) is a healthcare company listed in the US with a market value of about $431M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.2, a 5-year average ROIC of -66%.

About IRulya Therapeutics

IRulya Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 50% over three years (dilution for shareholders).

Score: 0.8 / 5

Value2/5
Future growth0/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.2
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-10.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-65.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue————————
Net income-$84M-$57M-$31M-$52M-$90M-$77M-$37M-$12M
Free cash flow-$42M-$32M-$18M-$44M-$63M-$51M-$33M-$12M
EPS (diluted)$-1.68$-1.31$-0.84$-1.54$-3.03$-2.63$-1.94$-3.71
Net margin————————
ROIC—-100.7%-34.8%-51.2%-75.4%-45.7%-33.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $76.12, 91% above the current price; targets range from $65.00 to $98.00; the consensus rating is “Strong buy”; expected EPS is $-5.00 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is IRulya Therapeutics’s P/E ratio?

About 0.2, based on the last twelve months of diluted earnings per share.

Does IRulya Therapeutics pay a dividend?

Not currently.

Is IRulya Therapeutics a good stock to buy?

We do not give buy or sell advice. IRulya Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.